Consun Pharmaceutical Group (HKSE:01681) 3-Year EBITDA Growth Rate : 10.30% (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Consun Pharmaceutical Group 3-Year EBITDA Growth Rate?

Consun Pharmaceutical Group's EBITDA per Share for the six months ended in Dec. 2023 was HK$0.68.

During the past 12 months, Consun Pharmaceutical Group's average EBITDA Per Share Growth Rate was 12.20% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 10.30% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 18.60% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 14.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Consun Pharmaceutical Group was 56.40% per year. The lowest was -16.10% per year. And the median was 12.20% per year.

Competitive Comparison of Consun Pharmaceutical Group's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Consun Pharmaceutical Group's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Consun Pharmaceutical Group's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Consun Pharmaceutical Group's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Consun Pharmaceutical Group's 3-Year EBITDA Growth Rate falls into.

Consun Pharmaceutical Group 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Consun Pharmaceutical Group (HKSE:01681) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Consun Pharmaceutical Group 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Consun Pharmaceutical Group's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Consun Pharmaceutical Group (HKSE:01681) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Consun Pharmaceutical Group Ltd (HKSE:01681) » Definitions » 3-Year EBITDA Growth Rate

Traded in Other Exchanges

C1P:Germany

Address

71, Dongpeng Avenue, Eastern section, Guangzhou Economic and Technological Development, Guangzhou, CHN

Website

https://www.chinaconsun.com

Consun Pharmaceutical Group Ltd is a biotechnology company with sales operations throughout China. Its principal activities are making and selling pharmaceutical products. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Consun derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.

Executives

An Yubao	2101 Beneficial owner
Li Qian	2101 Beneficial owner
Central Success Developments Limited	2101 Beneficial owner
Aali Resources Limited	2201 Interest of corporation controlled by you
Bos Trustee Limited	2301 Trustee
Zhang Lihua	2202 Interest of your spouse
An Meng	2101 Beneficial owner
Double Grace International Limited	2101 Beneficial owner
Bos Trustee Limited As Trustee	2201 Interest of corporation controlled by you

Consun Pharmaceutical Group (HKSE:01681) Headlines

No Headlines